Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.37 |
| ▸ | HTR6 | P50406 | 5/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918141 | 0.86 | HTR6 (0.37) | AURKAAURKBHTR6DRD2HTR2A | |
| SCHEMBL2924481 | 0.83 | AURKA (0.33) | AURKAAURKBHTR6GSK3BSRC | |
| SCHEMBL3037823 | 0.81 | HTR6 (0.37) | AURKBHTR6DRD2HTR2AGSK3B | |
| SCHEMBL2919416 | 0.80 | AURKA (0.38) | AURKAAURKBGSK3BSRCGSK3A | |
| SCHEMBL13221384 | 0.79 | JAK2 (0.49) | AURKAAURKBJAK2 | |
| SCHEMBL2916720 | 0.79 | SYK (0.41) | AURKAAURKBGSK3BSRCGSK3A | |
| SCHEMBL2924820 | 0.78 | AURKA (0.54) | AURKAAURKBGSK3BSRCGSK3A | |
| SCHEMBL4179393 | 0.76 | AURKA (0.44) | AURKAAURKBHTR6GSK3BSRC | |
| SCHEMBL4182422 | 0.76 | AURKA (0.48) | AURKAAURKBHTR6GSK3BSRC | |
| SCHEMBL13175816 | 0.75 | AURKA (0.38) | AURKAAURKBHTR6GSK3BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812439-B2 | KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-06 | — | — | EP | claimed |
| EP-1812439-B1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | claimed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | claimed |
| JP-2008516973-A | — | — | 2008-05-22 | — | — | JP | claimed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | claimed |
| EP-1812439-B2 | KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| EP-1812439-B1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AURKA 161/4885AURKB 122/4885HTR6 2795/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | AURKA 161/4885AURKB 122/4885HTR6 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.